Vaisala Corporation: Share Repurchase 15.8.2025
STOCK EXCHANGE RELEASE 15.8.2025
Vaisala Corporation: Share Repurchase 15.8.2025
In the Helsinki Stock Exchange
Trade date
15.8.2025
Bourse trade
Buy
Share
VAIAS
Amount
400
Shares
Average price/ share
47,0000
EUR
Total cost
18 800,00
EUR
Vaisala Corporation now holds a total of 137 384 shares
including the shares repurchased on 15.8.2025
The share buybacks are executed in compliance with Regulation
No. 596/2014 of the European Parliament and Council (MAR) Article 5
and the Commission Delegated Regulation (EU) 2016/1052.
On behalf of Vaisala Corporation
Nordea Bank Oyj
Sami Huttunen
Ilari Isomäki
More information:Niina Ala-Luopa+358 400 728 957, ir@vaisala.com
Distribution:Nasdaq HelsinkiKey mediavaisala.com
Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. www.vaisala.comAttachment
Vaisala 15.8 trades
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Should You Think About Buying LION E-Mobility AG (ETR:LMIA) Now?
LION E-Mobility AG (ETR:LMIA), is not the largest company out there, but it led the XTRA gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the company has traded much higher in the past year. Less-covered, small caps tend to present more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Let's take a look at LION E-Mobility's outlook and value based on the most recent financial data to see if the opportunity still exists. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. What's The Opportunity In LION E-Mobility? Good news, investors! LION E-Mobility is still a bargain right now. According to our valuation, the intrinsic value for the stock is €2.18, but it is currently trading at €1.41 on the share market, meaning that there is still an opportunity to buy now. However, given that LION E-Mobility's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for LION E-Mobility What kind of growth will LION E-Mobility generate? Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. LION E-Mobility's earnings over the next few years are expected to increase by 100%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What This Means For You Are you a shareholder? Since LMIA is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation. Are you a potential investor? If you've been keeping an eye on LMIA for a while, now might be the time to enter the stock. Its prosperous future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy LMIA. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision. If you want to dive deeper into LION E-Mobility, you'd also look into what risks it is currently facing. To that end, you should learn about the 4 warning signs we've spotted with LION E-Mobility (including 1 which is significant). If you are no longer interested in LION E-Mobility, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
7 minutes ago
- Yahoo
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure?
CRISPR Therapeutics AG recently reported its second quarter 2025 earnings, posting revenue of US$892,000, up from US$517,000 a year ago, but recording a net loss of US$208.55 million, up from US$126.41 million in the same period last year. Despite modest revenue gains, the significantly wider loss per share suggests rising costs or investment pressures are impacting the company's financial trajectory. We'll explore how the widening net loss and higher reported expenses could reshape CRISPR Therapeutics' investment narrative going forward. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. What Is CRISPR Therapeutics' Investment Narrative? To be a shareholder in CRISPR Therapeutics, you need conviction in the promise of gene-editing breakthroughs and the company's ability to translate pipeline progress into eventual commercial returns. The latest earnings report, though, spotlights a widening net loss and sharply higher operating expenses. While ongoing clinical trials and recent index inclusions remain key near-term catalysts, the size of the reported quarterly loss raises questions around cash burn and the timeline to profitability. This new financial data could shift expectations for the pace of hiring, R&D investment, or the need for additional funding, potentially affecting sentiment around CRISPR's risk profile. On balance, the recent news does not appear to instantly derail the main product development catalysts investors were tracking, but it sharpens focus on the sustainability of current spending levels and paths to revenue growth in a high-cost environment. But with losses widening, funding needs are something every investor should watch closely. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be. Exploring Other Perspectives Eighteen members of the Simply Wall St Community offer fair value estimates for CRISPR Therapeutics, ranging from US$14.57 to US$150.97 per share. As these forecasts reveal, opinions differ widely on the company's trajectory, particularly given growing expenses flagged in the latest earnings. Exploring several alternative viewpoints can help you understand the breadth of market expectations. Explore 18 other fair value estimates on CRISPR Therapeutics - why the stock might be worth less than half the current price! Build Your Own CRISPR Therapeutics Narrative Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance. Ready For A Different Approach? Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped: Find companies with promising cash flow potential yet trading below their fair value. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Is this the FTSE 100's greatest recovery stock right now?
Investors remain unconvinced by Persimmon's (LSE:PSN) credentials as a potential FTSE 100 recovery stock. They are unmoved even after a largely impressive trading update on Wednesday (13 August). In it, the housebuilder said that 'our average sales price, sales, completions, planning approvals, active sites and forward order book' all rose in the six months to June. In fact, Persimmon's share price dropped again following the release. It's now down 6.3% in the year to date. Are investors missing a chance to snap up what could be an exceptional turnaround stock? The recovery continues The housebuilding industry's post-2023 rebound has been bumpy at times. But supported by steady interest rate cuts, its upward momentum continues. Persimmon's latest trading statement shows it remains firmly on the comeback trail. It showed housing revenues up 12% in the six months to June. Total completions rose 4%, and average selling prices improved 8%. Better sales volumes, married with self-help measures, pushed the company's underlying operating margin 10 basis points higher. Underlying operating profit increased 13%. The builder's robust performance means it remains confident of a sustained recovery over the medium term. Completions are tipped to increase in 2025, to 11,000-11,500 from 10,664 last year, and again to 12,000 in 2026. A full-year underlying operating margin of 14.2%-14.5% is also expected. That's up from 14.1% in 2024. So what's occurring then? Put simply, investors are considering the fragility of the housing market recovery. Given signs of stagnating economic growth and a deteriorating jobs market, I can hardly blame them. Persimmon itself has warned of the threat of 'geopolitical events and challenging market conditions, including uncertainty in advance of the Budget' in autumn. Yet, tough economic conditions, rising living costs, and increased Stamp Duty haven't derailed the industry's recovery, so far. Latest Halifax data showed average home prices up 0.4% in July, the fastest rate of growth so far in 2025. Persimmon also continues to ride high — net private sales rates were 0.61 in the five weeks from 30 June, up from 0.55 in the same 2024 period. With further interest rate cuts tipped, and fierce competition among Britain's lenders also helping buyer affordability, I'm confident the sector rebound can continue. I'm not alone — Halifax's head of mortgages Amanda Bryden expects 'house prices to follow a steady path of modest gains through the rest of the year'. A 45% return? Given this supportive backdrop, City analysts think Persimmon's share price can rebound sharply over the next 12 months. The average target among the 16 analysts with ratings on the housebuilder is £15.33 per share. That's up a stunning 38.4% from current levels. With the builder packing a huge 5.6% forward dividend yield, too, investors today might enjoy a total return just a shade below 45% over the next year. Near-term challenges threaten Persimmon's potential to be the FTSE 100's best recovery stock. But given its strong operational progress and the likelihood of further interest rate reductions, I think it's still a top UK share to consider. The post Is this the FTSE 100's greatest recovery stock right now? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Royston Wild has positions in Persimmon Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
